Respiratory syncytial virus (RSV)

RS viruses cause colds, flu-like illnesses and bronchiolitis mainly in the winter half-year. They often lead to hospitalisation. The monoclonal antibody Nirsevimab is available for infants since October 2024. It is covered by basic health insurance. In addition, two vaccines are currently available for people aged 60 and over. One of these is also approved as a vaccination for pregnant women to protect their newborns.

Top of page

Documents

Factsheet by the Federal Vaccination Commission: Routine immunisation against RSV with protective antibodies (PDF, 1 MB, 10.09.2024)

Consensus statement - recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®) (Sep 2024) (PDF, 507 kB, 10.09.2024)

Poster - Protect your baby with RSV prophylaxis (PDF, 832 kB, 11.10.2024)

Recommendations for RSV vaccination and other documents are available in German and French.

Last modification 27.11.2024